Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 319

Sort by

Sort Order Select

Journal Articles

Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845

David Fruman, PhD, Dennis Juarez, B.S., Grace Diep, Undergraduate, Falisha Nguyen, Undergraduate, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD

Blood (2019) 134 (Supplement_1): 4413.

https://doi.org/10.1182/blood-2019-131218

Published: 2019

Journal Articles

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Harish Kumar, PhD, Ujjal Kumar Mukherjee, PhD, Li Chen, PhD, Amit Kumar Mitra, PhD MSc, BSc

Blood (2019) 134 (Supplement_1): 5543.

https://doi.org/10.1182/blood-2019-131923

Published: 2019

Journal Articles

Molecular Characterization of EP300 Mutant Myeloid Neoplasia

Sunisa Kongkiatkamon, Yasunobu Nagata, MD PhD, Hassan Awada, Vera Adema, PhD, Cassandra M Kerr, MS, Kevin Fung, Francesca Gould, Christina Snider, Milo Co, Jibran Durrani, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 5043.

https://doi.org/10.1182/blood-2019-130986

Published: 2019

Journal Articles

Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

Michael Weickert, John Dillberger, John R. Mackey, Paul Wyatt, David Gray, Kevin Read, Christian Li, Audrey Parenteau, Luc G. Berthiaume

Blood (2019) 134 (Supplement_1): 3362.

https://doi.org/10.1182/blood-2019-124934

Published: 2019

Journal Articles

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

Tomasz Knurowski, PhD MD, Karen Clegg, PhD, Nigel Brooks, PhD, Fay Ashby, Neil A Pegg, PhD, William West, PhD, Harriet S Walter, Tim CP Somervaille, MD PhD, Steven Knapper, DM, Andrew Davies, MD PhD

Blood (2019) 134 (Supplement_1): 1266.

https://doi.org/10.1182/blood-2019-124797

Published: 2019

Journal Articles

RhoA Targeting Suppresses Cold-Induced Platelet Lesion and Allows Refrigerated Storage of Functional Human Platelets to Fourteen Days

Shailaja N Hegde, PhD, Huzoor Akbar, PhD, Shawnagay Nestheide, BS, Ashley M Wellendorf, B.S., Breanna Bohan, James F Johnson, Yi Zheng, PhD, Jose A Cancelas, MD

Blood (2019) 134 (Supplement_1): 99.

https://doi.org/10.1182/blood-2019-125359

Published: 2019

Journal Articles

A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL

Blood (2019) 134 (Supplement_1): 3758.

https://doi.org/10.1182/blood-2019-126910

Published: 2019

Journal Articles

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

Jaesung Seo, PhD, Li Li, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 3759.

https://doi.org/10.1182/blood-2019-130339

Published: 2019

Journal Articles

Tipifarnib Modulates Interferon (IFN)-γ-Inducible Genes in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Stephen Reeder, BSc, Clare Coveney, PhD, Sergio Rutella, MDPhDFRCPath

Blood (2019) 134 (Supplement_1): 2726.

https://doi.org/10.1182/blood-2019-124717

Published: 2019

Journal Articles

An Epigenetic Screen Identifies PRMT5 As a Target for Inhibition of FLT3-ITD AML Cell Growth in Combination with Tyrosine Kinase Inhibitors

Aditi Dhir, MD, Andrew J Paterson, PhD, Shaowei Qiu, MD, Amanda K Mullen, Nick R Anderson, BS, Ravi Bhatia, MD

Blood (2019) 134 (Supplement_1): 2524.

https://doi.org/10.1182/blood-2019-125178

Published: 2019

Journal Articles

CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma

Nigel Brooks, PhD, Meera Raja, PhD, Barbara W Young, PhD, Gary J Spencer, PhD, Tim CP Somervaille, MD PhD, Neil A Pegg, PhD

Blood (2019) 134 (Supplement_1): 2560.

https://doi.org/10.1182/blood-2019-124707

Published: 2019

Journal Articles

O-Glcnacylation Is Essential for Erythropoiesis

Matthew P Parker, BS, Halyna Fedosyuk, MS, Lesya V Novikova, PhD, Zhen Zhang, PhD, Chad Slawson, PhD, Kenneth R Peterson, PhD

Blood (2019) 134 (Supplement_1): 2218.

https://doi.org/10.1182/blood-2019-129468

Published: 2019

Journal Articles

Regulation of Erythroblast Protein Expression By an RNA Splicing Mechanism, Decoy Exon-Mediated Intron Retention

Marilyn Parra, Weiguo Zhang, PhD, Jonathan Vu, Mark DeWitt, John G Conboy, PhD

Blood (2019) 134 (Supplement_1): 3504.

https://doi.org/10.1182/blood-2019-131153

Published: 2019

Journal Articles

Improved Bone Marrow Homing of NK Cells through PM21 Particle Stimulated Enhancement of Fucosylation of E-Selectin Ligand

Jeremiah Oyer, BSc, Nitin Chakravarti, PhD, Robert Igarashi, PhD, Deborah Altamore, PhD, Dean Anthony Lee, MD PhD, Alicja Joanna Copik, PhD

Blood (2019) 134 (Supplement_1): 3598.

https://doi.org/10.1182/blood-2019-131137

Published: 2019

Journal Articles

KLF4 Is Needed for Optimal Hydroxyurea Induction of Gamma-Globin in K562 Cells

Alireza Paikari, MD, Ankush Goyal, MA, Celeste K. Kanne, BA, Vivien A. Sheehan, MD PhD

Blood (2019) 134 (Supplement_1): 971.

https://doi.org/10.1182/blood-2019-131214

Published: 2019

Journal Articles

Interest of a New Method for Free Plasma Heme Related Species Dosages in Sickle Cell Disease and Beta Thalassemia

Laurent Kiger, Sandia Adypagavane, Laura Bencheikh, PhD, Nicolas Hebert, Stephane Moutereau, MD, Frédéric Galactéros, MD PhD, Michael Marden, PhD, Yves Beuzard, MD, France Pirenne, MD PhD, Pablo Bartolucci, MD PhD

Blood (2019) 134 (Supplement_1): 3381.

https://doi.org/10.1182/blood-2019-130600

Published: 2019

Journal Articles

Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study

Clementine Sarkozy, MD, Franck Morschhauser, MD, Jean-Marie Michot, MD, Benjamin Suttle, Lionel Karlin, MD, Steven LE Gouill, MD PhD, Fabrice Jardin, MD PhD, Herve Tilly, MD, Charles Herbaux, MD, Gilles Andre Salles, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 4191.

https://doi.org/10.1182/blood-2018-99-113193

Published: 2018

Journal Articles

A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance of Acute Lymphoblastic Leukemia

Jianping Li, MD, Catalina Troche, PhD, Alok Swaroop, PhD, Marta Kulis, PhD, Jon Oyer, PhD, Christine Will, MS, Daphne Dupere-Richer, PhD, Alberto Riva, PhD, Crissandra Pipe, LATG, Sharon Norton, MS, Richard Lynn Bennett, PhD, Jonathan D. Licht, MD

Blood (2018) 132 (Supplement 1): 653.

https://doi.org/10.1182/blood-2018-99-116309

Published: 2018

Journal Articles

Predictive Factors for Survival in Sickle Cell Disease: A Cohort Study Using Etendard Data

Laurent Savale, MD PhD, Gylna Loko, MD, François Lionnet, Bernard Maitre, Anoosha Habibi, Jocelyn Inamo, Dora Bachir, MD, Françoise Driss, Vincent Audard, MDPhD, Etienne Audureau, Marc Humbert, Gerald Simonneau, Frédéric Galactéros, MDPhD, Florence Parent, Pablo Bartolucci, MD PhD

Blood (2018) 132 (Supplement 1): 7.

https://doi.org/10.1182/blood-2018-99-113767

Published: 2018

Journal Articles

KMT2E-Mediated Epigenetic Reprogramming Promotes the Sensitivity to All-Trans Retinoic Acid and Increases the Granulocytic Differentiation in AML Cells

Luciana Yamamoto Almeida, PhD, Isabel Weinhäuser, MSc, Diego Antonio Pereira-Martins, MSc, Josiane Lilian Schiavinato, PhD, Patrícia Vianna Bonini Palma, BSc, Camila Bonaldo, Cleide Lucia Silva, MSc, Juliana Oliveira Poltronieri, MSc, Larissa Cândido, MSc, Antonio R. Lucena-Araujo, PhD, Eduardo Magalhães Rego, MD PhD

Blood (2018) 132 (Supplement 1): 3838.

https://doi.org/10.1182/blood-2018-99-118478

Published: 2018

NARROW

Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Molecular Characterization of EP300 Mutant Myeloid Neoplasia

Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

RhoA Targeting Suppresses Cold-Induced Platelet Lesion and Allows Refrigerated Storage of Functional Human Platelets to Fourteen Days

A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

Tipifarnib Modulates Interferon (IFN)-γ-Inducible Genes in Acute Myeloid Leukemia

An Epigenetic Screen Identifies PRMT5 As a Target for Inhibition of FLT3-ITD AML Cell Growth in Combination with Tyrosine Kinase Inhibitors

CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma

O-Glcnacylation Is Essential for Erythropoiesis

Regulation of Erythroblast Protein Expression By an RNA Splicing Mechanism, Decoy Exon-Mediated Intron Retention

Improved Bone Marrow Homing of NK Cells through PM21 Particle Stimulated Enhancement of Fucosylation of E-Selectin Ligand

KLF4 Is Needed for Optimal Hydroxyurea Induction of Gamma-Globin in K562 Cells

Interest of a New Method for Free Plasma Heme Related Species Dosages in Sickle Cell Disease and Beta Thalassemia

Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study

A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance of Acute Lymphoblastic Leukemia

Predictive Factors for Survival in Sickle Cell Disease: A Cohort Study Using Etendard Data

KMT2E-Mediated Epigenetic Reprogramming Promotes the Sensitivity to All-Trans Retinoic Acid and Increases the Granulocytic Differentiation in AML Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only